BioArctic AB Class B · OMXSTO:BIOA_B

BioArctic AB Class B — FY2021 Earnings Presentation

21 slides from BioArctic AB Class B's earnings presentation, Feb 3, 2022

  1. Slide 1: Full Year Report January-December 2021

    Slide 1: Full Year Report January-December 2021

    BIOARCTIC AB (PUBL) NASDAQ STOCKHOLM: BIOA B Full Year Report January-December 2021 Stockholm, February 3, 2022 Gunilla Osswald, PhD, CEO Jan Mattsson, CFO BioArctic AB

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    Disclaimer • This presentation has been prepared and produced by BioArctic AB (publ) (“BioArctic”) solely for the benefit of investment analysis of BioArctic and may not be used for any other purpose. Unless otherwise stated, BioArctic is the source for all data contained in this presentation. Such

  3. Slide 3: BioArctic – a unique Swedish biopharma company

    Slide 3: BioArctic – a unique Swedish biopharma company

    BioArctic – a unique Swedish biopharma company Improving life for patients with central nervous system disorders High unmet need for disease-modifying treatments for Alzheimer’s and Parkinson’s diseases creates large commercial opportunity World-class research and development driven organization wit

  4. Slide 4: Attractive and well-balanced project portfolio combines partner and proprietary projects

    Slide 4: Attractive and well-balanced project portfolio combines partner and proprietary projects

    Attractive and well-balanced project portfolio combines fully- financed partner projects and cutting-edge proprietary projects Project Partner Discovery Preclinical Phase 1 Phase 2 Phase 3 ALZHEIMER’S DISEASE Lecanemab (BAN2401) (Clarity AD) Eisai1 Early Alzheimer’s disease3 Lecanemab (BAN2401) (AHE

  5. Slide 5: Long-standing and successful partnerships – de-risking clinical development and optimizing commercialization

    Slide 5: Long-standing and successful partnerships – de-risking clinical development and optimizing commercialization

    Long-standing and successful partnerships – de-risking clinical development and optimizing commercialization Alzheimer’s disease Parkinson’s disease Partner track record Approved product for symptoms associated with Parkinson’s disease Discovered and developed Used to treat confusion world’s best-se

  6. Slide 6: Q4 highlights

    Slide 6: Q4 highlights

    Q4 highlights Alzheimer’s disease – Lecanemab • Eisai initiated a rolling BLA submission under the accelerated approval pathway in September 2021. • In December, the second of three parts of the file was submitted • The submission is expected to be completed during H1 2022 • Lecanemab was granted Fa

  7. Slide 7: Lecanemab – broad late-stage clinical program

    Slide 7: Lecanemab – broad late-stage clinical program

    Lecanemab – broad late-stage clinical program Disease stage Early AD Pre-clinical AD MCI Mild AD Moderate AD Severe AD FDA guideline Stage 1 Stage 2 Stage 3 Stage 4 Stage 5 Stage 6 Clarity AD Phase 3 confirmatory study – AHEAD 3-45 Phase 3 Program – ongoing ongoing • Eisai and ACTC started new Phase

  8. Slide 8: Lecanemab – unique selectivity towards toxic soluble species of Aβ

    Slide 8: Lecanemab – unique selectivity towards toxic soluble species of Aβ

    Lecanemab – unique selectivity towards toxic soluble species of Aβ Neurotoxic forms Monomers Oligomers Protofibrils Fibrils 9 – 75 kDa >75 – 5000 kDa Soluble Insoluble lecanemab aducanumab gantenerumab Lecanemab had the highest preference for soluble protofibrils/oligomers versus monomeric and fibri

  9. Slide 9: Lecanemab – strongest reduction of brain amyloid and lowest ARIA-E incidence among competitors

    Slide 9: Lecanemab – strongest reduction of brain amyloid and lowest ARIA-E incidence among competitors

    Lecanemab – strongest reduction of brain amyloid and lowest ARIA-E incidence among competitors PET1) amyloid, centiloids ARIA-E2) incidence ~(78%) 120 ~(59%) 40% ~(71%) 100 ~(75%) ~(93%) 30% 80 60 20% 40 10% 20 0 0% Lecanemab Aducanumab Aducanumab Donanemab Gantenerumab Lecanemab Aducanumab Donanema

  10. Slide 10: Lecanemab – potential to lead the paradigm shift in the treatment of Alzheimer's disease

    Slide 10: Lecanemab – potential to lead the paradigm shift in the treatment of Alzheimer's disease

    Lecanemab – potential to lead the paradigm shift in the treatment of Alzheimer’s disease Increased likelihood for Opportunity to be first with Opportunity to differentiate Further development lecanemab success full approval in US and EU programs  Positive and consistent  Accelerated approval  Rap

  11. Slide 11: The next step on a transformational journey for BioArctic

    Slide 11: The next step on a transformational journey for BioArctic

    The next step on a transformational journey for BioArctic Establish commercial organization in the Nordic countries, with stepwise and timely recruitment, including support functions and IT infrastructure • Increase awareness about; • early Alzheimer’s disease, • current and future diagnostics incl

  12. Slide 12: Significant progress and expansion of the pipeline

    Slide 12: Significant progress and expansion of the pipeline

    Significant progress and expansion of the pipeline Parkinson’s disease Blood-brain barrier Alzheimer’s disease Other CNS disorders ABBV-0805 Brain Transporter (BT) Discovery stage Neurodegeneration • Potential disease • Continued development programs research modifying antibody in of Brain Transport

  13. Slide 13: Brain Transporter (BT) technology delivers biotherapeutics to the brain

    Slide 13: Brain Transporter (BT) technology delivers biotherapeutics to the brain

    Brain Transporter (BT) technology delivers biotherapeutics to the brain BT Novel platform achieves high exposure and broad brain distribution Brain Transporter technology 2nd – generation technology provide Rapid and global brain Short summary mediate transport across the BBB superior brain exposure

  14. Slide 14: TDP-43 – opportunity for ALS and other neurodegenerative disorders

    Slide 14: TDP-43 – opportunity for ALS and other neurodegenerative disorders

    TDP-43 – opportunity for ALS and other neurodegenerative ND3014 disorders Amyotrophic lateral sclerosis (ALS) – a debilitating rare disease • Progressive neurodegenerative disease characterized by motor neuron degeneration TDP-43 a promising target for ALS – an orphan disease indication Several muta

  15. Slide 15: Financial Summary

    Slide 15: Financial Summary

    Financial Summary 15 BioArctic AB

  16. Slide 16: Net revenues and operating profit/loss Q4 2021

    Slide 16: Net revenues and operating profit/loss Q4 2021

    Net revenues and operating profit/loss Q4 2021 Net Revenues (MSEK) OPEX by item (MSEK) Operating Profit/Loss (MSEK) 4 36 60 43 45 42 42 40 38 40 36 32 -21 11 20 7 8 7 7 4 5 -30 -29 -34 0 -38 -37 -39 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2020 2021 2020 2021 2020 2021

  17. Slide 17: Cash and net result Q4 2021

    Slide 17: Cash and net result Q4 2021

    Cash and net result Q4 2021 Cash Balance (MSEK) Cash Flow From Operating Net Result (MSEK) Activities (MSEK) 4 1 077 1 050 1 036 1 000 960 930 892 848 -9 -20 -13 -27 -29 -21 -19 -36 -35 -38 -39 -29 -34 -38 -38 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2020 2021 2020 202

  18. Slide 18: Upcoming news and closing remarks

    Slide 18: Upcoming news and closing remarks

    Upcoming news and closing remarks 18 BioArctic AB

  19. Slide 19: Upcoming news flow

    Slide 19: Upcoming news flow

    Upcoming news flow Alzheimer’s disease Parkinson’s disease Blood-brain barrier Other CNS disorders Lecanemab (Eisai) ABBV-0805 (AbbVie) Brain Transporter (BT) Neurodegeneration • Rolling submission for • Start Phase 2 technology platform • Data to be disclosed at accelerated approval in the US • Fur

  20. Slide 20: BioArctic: With Patients in Mind

    Slide 20: BioArctic: With Patients in Mind

    BioArctic: With Patients in Mind Great science Great projects Great partners Great people 20 BioArctic AB

  21. Slide 21: Contact and next report

    Slide 21: Contact and next report

    GUNILLA OSSWALD, CEO JAN MATTSSON, CFO OSKAR BOSSON, VP NEXT REPORT & IR COMMUNICATIONS & IR CONTACT • Next Report: Q1 Jan-Mar 2022 on April 28, 2022 • Contact: Oskar Bosson, VP Communications & IR +46 704 10 71 80 ir@bioarctic.se To subscribe to financial reports/press releases and for more informa

Source: Internet Archive copy of bioarctic.se

More decks from BioArctic AB Class B

All 27 BioArctic AB Class B decks